- Home
- BYSI vs ACET Comparison
BYSI vs ACET Comparison
Compare BYSI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BYSI | ACET |
|---|---|---|
| Founded | 2010 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 69.6M |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BYSI | ACET |
|---|---|---|
| Price | $1.63 | $7.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 19.8K | ★ 134.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $0.45 |
| 52 Week High | $3.44 | $9.05 |
Technical Indicators
Market Signals| Indicator | BYSI | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 49.02 |
| Support Level | $1.38 | $6.54 |
| Resistance Level | $1.81 | $8.46 |
| Average True Range (ATR) | 0.13 | 0.47 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 78.37 | 33.10 |
Price Performance
Historical ComparisonAbout BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.